These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1219 related articles for article (PubMed ID: 25599276)

  • 61. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
    Stege EM; Kros JM; de Bruin HG; Enting RH; van Heuvel I; Looijenga LH; van der Rijt CD; Smitt PA; van den Bent MJ
    Cancer; 2005 Feb; 103(4):802-9. PubMed ID: 15637687
    [TBL] [Abstract][Full Text] [Related]  

  • 62. IDH1 mutation is prognostic for diffuse astrocytoma but not low-grade oligodendrogliomas in patients not treated with early radiotherapy.
    Iwadate Y; Matsutani T; Hirono S; Ikegami S; Shinozaki N; Saeki N
    J Neurooncol; 2015 Sep; 124(3):493-500. PubMed ID: 26243269
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Intraoperative perception and estimates on extent of resection during awake glioma surgery: overcoming the learning curve.
    Lau D; Hervey-Jumper SL; Han SJ; Berger MS
    J Neurosurg; 2018 May; 128(5):1410-1418. PubMed ID: 28731401
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas.
    Chen R; Ravindra VM; Cohen AL; Jensen RL; Salzman KL; Prescot AP; Colman H
    Neurosurg Focus; 2015 Mar; 38(3):E2. PubMed ID: 25727224
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Surgical assessment of the insula. Part 2: validation of the Berger-Sanai zone classification system for predicting extent of glioma resection.
    Hervey-Jumper SL; Li J; Osorio JA; Lau D; Molinaro AM; Benet A; Berger MS
    J Neurosurg; 2016 Feb; 124(2):482-8. PubMed ID: 26339856
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Supratentorial hemispheric ependymomas: an analysis of 109 adults for survival and prognostic factors.
    Hollon T; Nguyen V; Smith BW; Lewis S; Junck L; Orringer DA
    J Neurosurg; 2016 Aug; 125(2):410-8. PubMed ID: 26745489
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Impact of adjuvant treatments on survival in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study.
    Koo T; Lim DH; Seol HJ; Dho YS; Kim IH; Chang JH; Lee J; Jung TY; Gwak HS; Cho KH; Hong CK; Lee IJ; Kim E; Kim JH; Hong YK; Jang HS; Kim CY; Kim IA; Kim SH; Kim YI; Kim EY; Kim WC; Hong S
    J Neurooncol; 2018 Nov; 140(2):445-455. PubMed ID: 30097825
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Molecular markers in low-grade gliomas: predictive or prognostic?
    Hartmann C; Hentschel B; Tatagiba M; Schramm J; Schnell O; Seidel C; Stein R; Reifenberger G; Pietsch T; von Deimling A; Loeffler M; Weller M;
    Clin Cancer Res; 2011 Jul; 17(13):4588-99. PubMed ID: 21558404
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Prognostic Factors in Lobar World Health Organization Grade II Astrocytomas.
    Waqar M; Hanif S; Brodbelt AR; Rathi N; Das K; Zakaria R; Walker C; Jenkinson MD
    World Neurosurg; 2015 Jul; 84(1):154-62. PubMed ID: 25779854
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305).
    Shibui S; Narita Y; Mizusawa J; Beppu T; Ogasawara K; Sawamura Y; Kobayashi H; Nishikawa R; Mishima K; Muragaki Y; Maruyama T; Kuratsu J; Nakamura H; Kochi M; Minamida Y; Yamaki T; Kumabe T; Tominaga T; Kayama T; Sakurada K; Nagane M; Kobayashi K; Nakamura H; Ito T; Yazaki T; Sasaki H; Tanaka K; Takahashi H; Asai A; Todo T; Wakabayashi T; Takahashi J; Takano S; Fujimaki T; Sumi M; Miyakita Y; Nakazato Y; Sato A; Fukuda H; Nomura K
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):511-21. PubMed ID: 23228988
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Metabolic approach for tumor delineation in glioma surgery: 3D MR spectroscopy image-guided resection.
    Zhang J; Zhuang DX; Yao CJ; Lin CP; Wang TL; Qin ZY; Wu JS
    J Neurosurg; 2016 Jun; 124(6):1585-93. PubMed ID: 26636387
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Combined IDH1 mutation and MGMT methylation status on long-term survival of patients with cerebral low-grade glioma.
    Tanaka K; Sasayama T; Mizukawa K; Takata K; Sulaiman NS; Nishihara M; Kohta M; Sasaki R; Hirose T; Itoh T; Kohmura E
    Clin Neurol Neurosurg; 2015 Nov; 138():37-44. PubMed ID: 26276726
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Intraoperative 3D ultrasound-guided resection of diffuse low-grade gliomas: radiological and clinical results.
    Bø HK; Solheim O; Kvistad KA; Berntsen EM; Torp SH; Skjulsvik AJ; Reinertsen I; Iversen DH; Unsgård G; Jakola AS
    J Neurosurg; 2020 Feb; 132(2):518-529. PubMed ID: 30717057
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma.
    Hervey-Jumper SL; Zhang Y; Phillips JJ; Morshed RA; Young JS; McCoy L; Lafontaine M; Luks T; Ammanuel S; Kakaizada S; Egladyous A; Gogos A; Villanueva-Meyer J; Shai A; Warrier G; Rice T; Crane J; Wrensch M; Wiencke JK; Daras M; Oberheim Bush NA; Taylor JW; Butowski N; Clarke J; Chang S; Chang E; Aghi M; Theodosopoulos P; McDermott M; Jakola AS; Kavouridis VK; Nawabi N; Solheim O; Smith T; Berger MS; Molinaro AM
    J Clin Oncol; 2023 Apr; 41(11):2029-2042. PubMed ID: 36599113
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The Value of Pre- and Intraoperative Adjuncts on the Extent of Resection of Hemispheric Low-Grade Gliomas: A Retrospective Analysis.
    Incekara F; Olubiyi O; Ozdemir A; Lee T; Rigolo L; Golby A
    J Neurol Surg A Cent Eur Neurosurg; 2016 Mar; 77(2):79-87. PubMed ID: 26216736
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Acute progression of untreated incidental WHO Grade II glioma to glioblastoma in an asymptomatic patient.
    Cochereau J; Herbet G; Rigau V; Duffau H
    J Neurosurg; 2016 Jan; 124(1):141-5. PubMed ID: 26162036
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Phase II TPDCV protocol for pediatric low-grade hypothalamic/chiasmatic gliomas: 15-year update.
    Mishra KK; Squire S; Lamborn K; Banerjee A; Gupta N; Wara WM; Prados MD; Berger MS; Haas-Kogan DA
    J Neurooncol; 2010 Oct; 100(1):121-7. PubMed ID: 20221671
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Impact of Resection on Survival of Isocitrate Dehydrogenase 1-Mutated World Health Organization Grade II Astrocytoma After Malignant Progression.
    Grau SJ; Hampl JA; Kohl AC; Timmer M; Duval IV; Blau T; Ruge MI; Goldbrunner RH
    World Neurosurg; 2017 Jul; 103():180-185. PubMed ID: 28377251
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas.
    Quon H; Abdulkarim B
    Cochrane Database Syst Rev; 2008 Apr; (2):CD007104. PubMed ID: 18425979
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas.
    McGirt MJ; Chaichana KL; Attenello FJ; Weingart JD; Than K; Burger PC; Olivi A; Brem H; Quinoñes-Hinojosa A
    Neurosurgery; 2008 Oct; 63(4):700-7; author reply 707-8. PubMed ID: 18981880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 61.